Literature DB >> 29280078

Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study.

Hsin-Yi Yang1, Herng-Sheng Lee2, Wan-Ting Huang1, Ming-Jer Chen3, Solomon Chih-Cheng Chen4,5, Yueh-Han Hsu6,7,8,9.   

Abstract

Polycystic ovary syndrome (PCOS) is a complex disorder; various features of this disorder may influence bone metabolism and skeletal mass. The contribution of PCOS to lower bone mineral density has been recognized. However, the impact of PCOS on the long-term risks for fractures remains inconclusive. The aim of this study was to determine the risk of overall fracture and fractures at different anatomic sites in patients with PCOS. Using a nationwide health insurance claims database, we included 11,106 subjects, aged 15-80 years, with newly diagnosed PCOS (ICD-9-CM: 254.4X) during 2000-2012. Patients with PCOS and respective age-matched (1:4) controls without PCOS were enrolled. The occurrence of fracture was monitored until the end of 2013. Cox regression and computed hazard ratios (HR) with 95% confidence intervals (95% CI) were used to determine the risk of PCOS among women with fractures. The PCOS and non-PCOS groups were comprised of 11,106 patients with PCOS and 44,424 participants without PCOS, respectively. Patients with PCOS had a higher incidence of any fractures compared with non-PCOS group (10.16 versus 8.07 per 1000 person-years) and a greater risk of any fractures [adjusted hazard ratio (aHR) = 1.23, 95% CI = 1.13-1.33], osteoporotic fractures (aHR = 1.33, 95% CI = 1.15-1.54), spine fractures (aHR = 1.36, 95% CI = 1.11-1.66) and forearm fractures (aHR = 1.39, 95% CI = 1.07-1.80), but the risk for femur or hip fracture, humerus, wrist and non-osteoporotic fractures were not increased. In conclusion, the PCOS group had a higher occurrence rate of fractures than the non-PCOS group. These results provide evidence for the adverse effects of PCOS on the risk of fractures.

Entities:  

Keywords:  Fracture; Polycystic ovary syndrome; Taiwan National Health Insurance Research Database

Mesh:

Year:  2017        PMID: 29280078     DOI: 10.1007/s00774-017-0894-8

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  44 in total

1.  Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome.

Authors:  Xiaoli Chen; Dongzi Yang; Lin Li; Shuying Feng; Liangan Wang
Journal:  Hum Reprod       Date:  2006-05-09       Impact factor: 6.918

2.  Relationship of volumetric bone density and structural parameters at different skeletal sites to sex steroid levels in women.

Authors:  Sundeep Khosla; B Lawrence Riggs; Richard A Robb; Jon J Camp; Sara J Achenbach; Ann L Oberg; Peggy A Rouleau; L Joseph Melton
Journal:  J Clin Endocrinol Metab       Date:  2005-07-05       Impact factor: 5.958

3.  Body composition, bone mineral density and fractures in late postmenopausal women with polycystic ovary syndrome - a long-term follow-up study.

Authors:  Johanna Schmidt; Eva Dahlgren; Mats Brännström; Kerstin Landin-Wilhelmsen
Journal:  Clin Endocrinol (Oxf)       Date:  2012-08       Impact factor: 3.478

Review 4.  Ethnic differences in the phenotypic expression of polycystic ovary syndrome.

Authors:  Yue Zhao; Jie Qiao
Journal:  Steroids       Date:  2013-04-25       Impact factor: 2.668

5.  Determinants of low bone mineral density in premenopausal polycystic ovary syndrome patients.

Authors:  Cihan Karadağ; Tevfik Yoldemir; Dilek Gogas Yavuz
Journal:  Gynecol Endocrinol       Date:  2016-12-02       Impact factor: 2.260

Review 6.  Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis.

Authors:  Lisa J Moran; Marie L Misso; Robert A Wild; Robert J Norman
Journal:  Hum Reprod Update       Date:  2010-02-16       Impact factor: 15.610

7.  Augmentation of cortical bone mineral density in women with polycystic ovary syndrome: a peripheral quantitative computed tomography (pQCT) study.

Authors:  D Kassanos; E Trakakis; C S Baltas; O Papakonstantinou; G Simeonidis; G Salamalekis; I Grammatikakis; G Basios; G Labos; G Skarantavos; A Balanika
Journal:  Hum Reprod       Date:  2010-06-14       Impact factor: 6.918

Review 8.  Diabetes mellitus, bone mineral density, and fracture risk.

Authors:  Elsa S Strotmeyer; Jane A Cauley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2007-12       Impact factor: 3.243

9.  Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome.

Authors:  Enrico Carmina; Rogerio A Lobo
Journal:  Fertil Steril       Date:  2004-09       Impact factor: 7.329

10.  Prevalence of polycystic ovary syndrome in women in China: a large community-based study.

Authors:  Rong Li; Qiufang Zhang; Dongzi Yang; Shangwei Li; Shulan Lu; Xiaoke Wu; Zhaolian Wei; Xueru Song; Xiuxia Wang; Shuxin Fu; Jinfang Lin; Yimin Zhu; Yong Jiang; Huai L Feng; Jie Qiao
Journal:  Hum Reprod       Date:  2013-06-27       Impact factor: 6.918

View more
  5 in total

1.  PCOS and risk of fractures.

Authors:  Yueh-Han Hsu; Hsin-Yi Yang
Journal:  J Bone Miner Metab       Date:  2018-03-08       Impact factor: 2.626

2.  PCOS and bone fractures.

Authors:  Fabio V Comim; Melissa O Premaor
Journal:  J Bone Miner Metab       Date:  2018-01-25       Impact factor: 2.626

3.  Exploring the relationship between osteoporosis and polycystic ovary syndrome based on bioinformatics.

Authors:  Chun-Xiao Dang; Ding Wang; Xiao Yu; Peng-Fei Liu; Jin-Xing Liu
Journal:  Medicine (Baltimore)       Date:  2022-06-24       Impact factor: 1.817

Review 4.  The Relationship Between Polycystic Ovarian Syndrome, Periodontal Disease, and Osteoporosis.

Authors:  Hannah E Young; Wendy E Ward
Journal:  Reprod Sci       Date:  2020-09-10       Impact factor: 3.060

Review 5.  Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy.

Authors:  Jia-Feng Chen; Pei-Wen Lin; Yi-Ru Tsai; Yi-Chien Yang; Hong-Yo Kang
Journal:  Cells       Date:  2019-10-25       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.